Information Provided By:
Fly News Breaks for February 29, 2016
OREX
Feb 29, 2016 | 07:47 EDT
JPMorgan analyst Jessica Fye downgraded Orexigen to Neutral from Overweight as she sees little in the near-term that will encourage new investors to get involved in the stock and believes management will need to demonstrate execution on at least one partnership outside of the U.S., and possibly more, before investors have faith in its guidance that the company could become profitable by late 2018.
News For OREX From the Last 2 Days
There are no results for your query OREX